Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.
| Revenue (Most Recent Fiscal Year) | $451.36M |
| Net Income (Most Recent Fiscal Year) | $-66.42M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.29 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -6.49% |
| Net Margin (Trailing 12 Months) | -7.67% |
| Return on Equity (Trailing 12 Months) | -13.53% |
| Return on Assets (Trailing 12 Months) | -8.12% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.20 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.21 |
| Inventory Turnover (Trailing 12 Months) | 9.50 |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.43 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.59 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 43.88M |
| Free Float | 39.65M |
| Market Capitalization | $3.22B |
| Average Volume (Last 20 Days) | 0.74M |
| Beta (Past 60 Months) | 0.53 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.64% |
| Percentage Held By Institutions (Latest 13F Reports) | 90.01% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |